Consensus Novartis AG Nyse

Equities

NVS

US66987V1098

Real-time Estimate Cboe BZX 09:56:12 2024-06-07 am EDT 5-day change 1st Jan Change
105.7 USD -0.37% Intraday chart for Novartis AG +2.65% +4.84%

Evolution of the average Target Price on Novartis AG

Price target over the last 5 years

History of analyst recommendation changes

6956cc7687e1aa43874f71cf1e5dbe2a.nxC1qzNCRCH8q5gwaNyXoZtJxefb-ypU1HWBIj1vdSg.z0Tsz3QJNWzF7dtVMrrWyKkzrZ-Vil8ZvgLUG1wpOx3USYfTaQkQbKnxqA~bdb93ca8222f8d157c0dbc4ea65c480f
AlphaValue/Baader Europe Lowers Price Target on Novartis, Maintains Add Recommendation MT
Staff at drugmaker under U.S. scrutiny worked with Chinese military scientists RE
NOVARTIS AG : Deutsche Bank maintains a Buy rating ZD
Bank Vontobel Lifts Price Target on Novartis, Maintains Buy Recommendation MT
NOVARTIS AG : JP Morgan remains Neutral ZD
NOVARTIS AG : Buy rating from Goldman Sachs ZD
NOVARTIS : UBS reiterates buy recommendation after ASCO CF
NOVARTIS AG : UBS gives a Buy rating ZD
NOVARTIS AG : UBS reiterates its Buy rating ZD
NOVARTIS AG : Jefferies remains its Buy rating ZD
Goldman Sachs Starts Novartis With Buy Rating, $120 Price Target MT
NOVARTIS AG : From Sell to buy Rating by Goldman Sachs ZD
NOVARTIS AG : Deutsche Bank remains its Buy rating ZD
Berenberg Raises Price Target on Novartis to CHF77 From CHF74, Maintains Hold Rating MT
NOVARTIS AG : Berenberg remains Neutral ZD
NOVARTIS AG : UBS maintains a Buy rating ZD
NOVARTIS AG : Receives a Buy rating from Jefferies ZD
BMO Capital Adjusts Price Target on Novartis to $116 From $114, Maintains Market Perform Rating MT
NOVARTIS AG : UBS reaffirms its Buy rating ZD
NOVARTIS AG : Deutsche Bank gives a Buy rating ZD
NOVARTIS AG : JP Morgan remains Neutral ZD
NOVARTIS : 2024 has started on a strong note; guidance upgraded Alphavalue
NOVARTIS AG : JP Morgan gives a Neutral rating ZD
NOVARTIS AG : Barclays keeps a Sell rating ZD
NOVARTIS : Oddo BHF confirms its recommendation on the share CF
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
106.5 USD
Average target price
110.2 USD
Spread / Average Target
+3.47%
High Price Target
131.7 USD
Spread / Highest target
+23.68%
Low Price Target
84.2 USD
Spread / Lowest Target
-20.92%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Novartis AG

AlphaValue
DEUTSCHE BANK RESEARCH Emmanuel Papadakis
Baader Bank
JPMORGAN Richard Vosser
UBS Matthew Weston
JEFFERIES Peter Welford
GOLDMAN SACHS James Quigley
Berenberg Bank
BERENBERG Kerry Holford
BMO Capital
BARCLAYS Emily Field
DZ BANK Elmar Kraus
Kepler Capital Markets
Societe Generale
Redburn
Stifel Nicolaus
BNP Paribas
MORGAN STANLEY Mark Purcell
Barrington Research
Credit Suisse
International Strategy & Investment Group
Morningstar
ODDO BHF
DA Davidson
Zacks Equity Research
Bank of America Securities/Merrill Lynch
BERNSTEIN RESEARCH Wimal Kapadia
Kepler Cheuvreux
Wolfe Research
AltaCorp Capital
DEUTSCHE BANK Emmanuel Papadakis
HSBC
Exane BNP Paribas
Bryan, Garnier & Co.
Deutsche Bank Securities
Moody's Investors Service
Dundee
Exane BNP
Bernstein
Argus
Cowen
BRYAN GARNIER Eric Le Berrigaud
LIBERUM CAPITAL Graham Doyle
BANK OF AMERICA (BOFA) Graham Parry
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings